The potential role of Epigallocatechin-3-Gallate (EGCG) in breast cancer treatment

Publication type
Access rights
Open access
Terms of use
Appears in Collections:
Breast cancer is one of the most diagnosed cancers worldwide, with an incidence of 47.8%. Its treatment includes surgery, radiotherapy, chemotherapy, and antibodies giving a mortality of 13.6%. Breast tumor development is driven by a variety of signaling pathways with high heterogeneity of surface receptors, which makes treatment difficult. Epigallocatechin-3-gallate (EGCG) is a natural polyphenol isolated as the main component in green tea; it has shown multiple beneficial effects in breast cancer, controlling proliferation, invasion, apoptosis, inflammation, and demethylation of DNA. These properties were proved in vitro and in vivo together with synergistic effects in combination with traditional chemotherapy, increasing the effectiveness of the treatment. This review focuses on the effects of EGCG on the functional capabilities acquired by breast tumor cells during its multistep development, the molecular and signal pathways involved, the synergistic effects in combination with current drugs, and how nanomaterials can improve its bioavailability on breast cancer treatment.
Marín V, Burgos V, Pérez R, Maria DA, Pardi P, Paz C. The potential role of Epigallocatechin-3-Gallate (EGCG) in breast cancer treatment. Int J Mol Sci. 2023 Jun; 24(13):10737. doi:10.3390/ijms241310737.
Link to cite this reference
Issue Date

Files in This Item:

Size: 1.13 MB
Format: Adobe PDF
Show full item record

This item is licensed under a Creative Commons License Creative Commons